Aptose Biosciences price target raised to $38 from $6 at Cantor Fitzgerald

Cantor Fitzgerald analyst Li Watsek raised the firm’s price target on Aptose Biosciences to $38 from $6 and keeps an Overweight rating on the shares. The price target increase is due to the 15:1 reverse stock split and $25M common stock financing announced earlier this month, the analyst tells investors in a research note.